- Home
- ENX vs BMEA Comparison
ENX vs BMEA Comparison
Compare ENX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- BMEA
- Stock Information
- Founded
- ENX 2002
- BMEA 2017
- Country
- ENX United States
- BMEA United States
- Employees
- ENX N/A
- BMEA N/A
- Industry
- ENX Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- BMEA Health Care
- Exchange
- ENX Nasdaq
- BMEA Nasdaq
- Market Cap
- ENX 178.4M
- BMEA 275.6M
- IPO Year
- ENX N/A
- BMEA 2021
- Fundamental
- Price
- ENX $9.83
- BMEA $11.42
- Analyst Decision
- ENX
- BMEA Buy
- Analyst Count
- ENX 0
- BMEA 13
- Target Price
- ENX N/A
- BMEA $36.33
- AVG Volume (30 Days)
- ENX 25.4K
- BMEA 1.0M
- Earning Date
- ENX 01-01-0001
- BMEA 10-28-2024
- Dividend Yield
- ENX 3.94%
- BMEA N/A
- EPS Growth
- ENX N/A
- BMEA N/A
- EPS
- ENX 0.16
- BMEA N/A
- Revenue
- ENX N/A
- BMEA N/A
- Revenue This Year
- ENX N/A
- BMEA N/A
- Revenue Next Year
- ENX N/A
- BMEA N/A
- P/E Ratio
- ENX $61.00
- BMEA N/A
- Revenue Growth
- ENX N/A
- BMEA N/A
- 52 Week Low
- ENX $7.84
- BMEA $3.61
- 52 Week High
- ENX $10.07
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- ENX 47.05
- BMEA 68.67
- Support Level
- ENX $9.74
- BMEA $10.35
- Resistance Level
- ENX $9.83
- BMEA $11.83
- Average True Range (ATR)
- ENX 0.07
- BMEA 0.93
- MACD
- ENX -0.01
- BMEA 0.02
- Stochastic Oscillator
- ENX 34.48
- BMEA 58.54
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.